Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2023 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | 100.00% |
| Net profit | -54.67k | 102.06% |
| EBITDA | -23.29k | 100.84% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €206.43k |
Number of shares | 4.64m |
52-week high/low | €0.72 - €0.0445 |
| Dividends | No |
Beta | 0.17 |
P/E ratio | -100.00 |
PEG ratio | 1.02 |
P/B ratio | -14.28 |
P/S ratio | 0.00 |
Company profile
WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat central nervous system tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of glioblastoma multiforme that is in the pre-clinical trial; and Annamycin to treat acute myeloid leukemia (AML) and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
| Name | WPD Pharmaceuticals |
| CEO | Mariusz Olejniczak |
| Headquarters | Vancouver,
bc Poland |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 13/01/2020 |
| Employees | 16 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Cnq | WBIO.CN |
Pnk | WPDPF |
Hamburg | 8SV1.HM |
München | 8SV1.MU |